Skip to content
Evigrade
MajorImmunosuppressants. Calcineurin inhibitors×Direct oral anticoagulants (factor Xa inhibitors)

Updated · Methodology

Mechanism

Edoxaban is a substrate of the efflux transporter P-glycoprotein (P-gp). Ciclosporin inhibits this transporter, so edoxaban plasma levels rise (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA; ciclosporin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Single doses of ciclosporin 500 mg and edoxaban 60 mg taken together increased the edoxaban area under the concentration–time curve (AUC) by 73% and its peak concentration by 74% (edoxaban SmPC, EMA). The kidneys account for about half of total edoxaban clearance (edoxaban SmPC, EMA), and ciclosporin often raises serum creatinine and urea (ciclosporin SmPC, AEMPS). People taking ciclosporin were excluded from the main edoxaban trials, so the combination has not been studied in patients (edoxaban label, US Food and Drug Administration, FDA).

Symptoms

The main risk is bleeding. It can occur at any site and can be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Gastrointestinal bleeding, vaginal bleeding and bleeding into the skin are common. Intracranial bleeding is uncommon, and menstrual bleeding may become heavier or last longer (edoxaban SmPC, EMA). Bleeding can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause. An unexplained fall in haemoglobin or blood pressure points to hidden bleeding (edoxaban SmPC, EMA).

Management

With ciclosporin, the recommended edoxaban dose is 30 mg once daily instead of the usual 60 mg. This applies both in atrial fibrillation and in deep vein thrombosis and pulmonary embolism (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The European Heart Rhythm Association table gives the same dose for this pair (EHRA 2021). Several reasons for reduction do not lower the dose further. With creatinine clearance of 15–50 mL/min or body weight of 60 kg or less as well, it stays at 30 mg (edoxaban SmPC, EMA). The ciclosporin SmPC contraindicates combinations with P-glycoprotein (P-gp) substrates whose high plasma levels are linked to serious or life-threatening adverse reactions. Its examples are bosentan, dabigatran and aliskiren, and edoxaban is not among them (ciclosporin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Check kidney function often, because ciclosporin can impair it (ciclosporin SmPC, AEMPS). To set the edoxaban dose, calculate creatinine clearance with the Cockcroft–Gault formula before treatment. Calculate it again whenever kidney function may have changed, including because of other medicines (edoxaban SmPC, EMA). Edoxaban is not recommended in patients with creatinine clearance below 15 mL/min or on dialysis (edoxaban SmPC, EMA). Promptly evaluate any signs of blood loss (edoxaban label, US Food and Drug Administration, FDA). Haemoglobin and haematocrit may help detect hidden bleeding. Stop edoxaban if severe bleeding occurs (edoxaban SmPC, EMA). There is no specific antidote, and haemodialysis removes little edoxaban. For life-threatening bleeding that cannot be controlled, the SmPC describes a 4-factor prothrombin complex concentrate at 50 IU/kg. It reversed the effects of edoxaban 30 minutes after the end of the infusion (edoxaban SmPC, EMA). In the USA, the edoxaban dose for atrial fibrillation is not reduced because of P-gp inhibitors. The US label also states that edoxaban has not been studied with ciclosporin in patients (edoxaban label, FDA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Ciclosporin

Other interactions with Edoxaban